Zacks Research Forecasts Reduced Earnings for Globus Medical

Key Points

• Zacks Research trimmed its FY2026 EPS estimate for Globus Medical to $4.40 from $4.42 while maintaining a "Strong-Buy" rating; the consensus full-year EPS is $4.46.
• Globus Medical's most recent quarter beat expectations with $1.28 EPS versus $1.06 expected and revenue of $826.4M, up 25.7% year-over-year, showing strong top-line growth and an 18.3% net margin.
• Analyst sentiment is broadly positive—MarketBeat rates the stock a "Moderate Buy" with a $104.36 target—while the share price is trading near $95 amid notable insider selling and very high institutional ownership.

Globus Medical, Inc. (NYSE:GMED - Free Report) - Zacks Research cut their FY2026 earnings estimates for shares of Globus Medical in a research report issued on Thursday, April 23rd. Zacks Research analyst Team now expects that the medical device company will post earnings per share of $4.40 for the year, down from their previous forecast of $4.42. Zacks Research currently has a "Strong-Buy" rating on the stock. The consensus estimate for Globus Medical's current full-year earnings is $4.46 per share. Zacks Research also issued estimates for Globus Medical's Q4 2026 earnings at $1.35 EPS and Q3 2027 earnings at $1.21 EPS.

Globus Medical (NYSE:GMED - Get Free Report) last issued its quarterly earnings results on Tuesday, February 24th. The medical device company reported $1.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.06 by $0.22. The company had revenue of $826.42 million during the quarter, compared to analyst estimates of $803.29 million. Globus Medical had a net margin of 18.30% and a return on equity of 12.57%. Globus Medical's quarterly revenue was up 25.7% compared to the same quarter last year. During the same period last year, the business earned $0.84 EPS.

A number of other analysts have also weighed in on GMED. BTIG Research restated a "neutral" rating on shares of Globus Medical in a research note on Tuesday, December 30th. Truist Financial set a $115.00 price objective on shares of Globus Medical in a research note on Wednesday, February 25th. Wells Fargo & Company upgraded shares of Globus Medical to a "strong-buy" rating in a research note on Wednesday, March 18th. Wall Street Zen upgraded shares of Globus Medical from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 3rd. Finally, TD Cowen upgraded shares of Globus Medical to a "strong-buy" rating in a research note on Tuesday, January 27th. Three analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and five have issued a Hold rating to the company's stock. Based on data from MarketBeat, Globus Medical presently has an average rating of "Moderate Buy" and a consensus target price of $104.36.

Globus Medical Stock Performance

NYSE:GMED opened at $95.05 on Monday. The firm has a market cap of $12.86 billion, a P/E ratio of 24.12, a P/E/G ratio of 2.22 and a beta of 1.09. Globus Medical has a fifty-two week low of $51.79 and a fifty-two week high of $101.40. The firm has a 50-day simple moving average of $90.00 and a two-hundred day simple moving average of $85.11.

Insider Activity at Globus Medical

In other news, EVP Kelly Huller sold 20,000 shares of Globus Medical stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total value of $1,890,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 18.54% of the stock is owned by corporate insiders.

Institutional Trading of Globus Medical

A number of large investors have recently made changes to their positions in the stock. Strs Ohio grew its stake in shares of Globus Medical by 29.7% in the first quarter. Strs Ohio now owns 110,782 shares of the medical device company's stock worth $9,545,000 after acquiring an additional 25,396 shares during the period. Root Financial Partners LLC grew its stake in shares of Globus Medical by 291.5% in the first quarter. Root Financial Partners LLC now owns 779 shares of the medical device company's stock worth $67,000 after acquiring an additional 580 shares during the period. Trust Investment Advisors bought a new stake in shares of Globus Medical in the first quarter worth approximately $1,028,000. SMART Wealth LLC bought a new stake in shares of Globus Medical in the first quarter worth approximately $273,000. Finally, Inspire Investing LLC grew its stake in shares of Globus Medical by 234,962.5% in the first quarter. Inspire Investing LLC now owns 18,805 shares of the medical device company's stock worth $1,620,000 after acquiring an additional 18,797 shares during the period. 95.16% of the stock is currently owned by institutional investors.

Globus Medical Company Profile

Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.